Gabapentin
Product Images NDC 64725-0221

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 64725-0221). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 0221)

Label for Gabapentin 100 mg capsules, originally manufactured by Invagen and repackaged by TYA Pharmaceuticals in Tallahassee, FL. The label includes Rx only designation, a lot number placeholder, expiration date placeholder, and contact information. Dosage instructions refer to the package insert.*

FDA Label Image

Label Image (64725 0222)

Label for Gabapentin 300 mg capsules in a 100-count bottle. The label indicates the product is prescription only, with a lot number placeholder and expiration date placeholder. The manufacturer is Invagen, and the product is repackaged by TYA Pharmaceuticals in Tallahassee, FL. A barcode and a note to see package insert for dosing are also shown.*

FDA Label Image

7d5ebe51-figure-01 (7d5ebe51 Figure 01)

Chemical structure diagram showing the molecular formula of gabapentin, an active ingredient used in pharmaceutical products. The diagram includes a cyclohexane ring with attached functional groups representing the compound's chemical composition.*

FDA Label Image

7d5ebe51-figure-02 (7d5ebe51 Figure 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The x-axis shows time in weeks including a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis represents the mean pain score. Gabapentin shows a decreasing pain score trend compared to placebo with statistically significant differences (p < 0.01) indicated.*

FDA Label Image

7d5ebe51-figure-03 (7d5ebe51 Figure 03)

A line graph showing mean pain scores over 7 weeks comparing placebo with Gabapentin at 1800 mg/day and 2400 mg/day doses. The chart marks a 3-week dose titration period followed by a 4-week fixed dose period, illustrating decreasing pain scores over time for both Gabapentin groups compared to placebo.*

FDA Label Image

7d5ebe51-figure-04 (7d5ebe51 Figure 04)

A bar chart comparing the percentage of responders at endpoint for two studies. Study 1 shows results for placebo (PBO) at 12% and Gabapentin (GBP) 3600 with 29%. Study 2 shows placebo (PBO) at 14%, Gabapentin (GBP) 1800 at 32%, and GBP 2400 at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

7d5ebe51-figure-05 (7d5ebe51 Figure 05)

A scatter plot chart showing the percentage difference on the y-axis versus daily dose in mg on the x-axis for gabapentin. The chart compares results from three studies labeled as STUDY a, STUDY b, and STUDY c, with data points at 600, 900, 1200, and 1800 mg daily doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.